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Abstract
Background—Recent reports suggest that endotoxin exposure can blunt phagocyte functions. The
aim of this study was to examine whether lung phagocytic cells have altered host defense function
in young cystic fibrosis (CF) patients, and to explore the contribution of neutrophil elastase (NE) and
surfactant proteins to these effects.
Methods—BALF cells from CF children (N=12) and disease controls (N=12) were analyzed by
flow cytometry for mCD14 and HLA-DR expression and phagocytosis. The effects of exogenous
surfactant protein A and D (SP-A,D) and proteases on BALF cells in short-term culture were assessed
experimentally.
Results—Expression of the surface markers mCD14 and HLA-DR, and phagocytosis, were all
blunted on CF phagocytes compared to disease controls (p<0.05). In CF phagocytes, SP-A enhanced
both phagocytosis and mCD14 expression (p<0.05). Both CF BALF and NE reduced phagocytosis
and expression of mCD14 and HLA-DR (p<0.05) by non-CF phagocytes; the latter effect was
attenuated by protease inhibitor.
Conclusion—CF airway phagocytes appear to have altered host defense functions that could
contribute to poor bacterial clearance. These impairments can be reproduced by incubation of non-
CF cells with NE, while SP-A can partially reverse them. Decreasing protease activity and increasing
collectin activity may be beneficial in early CF.
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1. Introduction
Chronic bacterial airways infection and subsequent intense neutrophilic inflammation with
release of intracellular proteases are considered the main contributors to bronchiectasis and
end-stage lung disease in cystic fibrosis (CF) [1,2]. Recent research has demonstrated the
additional importance of inflammation and immune response in CF airway disease [3,4,5].
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Observations raising concern about primary or secondary immunologic abnormalities in CF
include the excessive inflammation in infancy, the persistence of neutrophilic inflammation,
and the inability to clear bacteria despite this intense response. Clearance of lung infection
involves antigen recognition, presentation to effector cells, phagocytosis and killing.
Macrophages and polymorphonuclear neutrophils (PMN) are the prototypic cells of innate
immune response. They play a central role in innate immunity through expression of receptors
that recognize and mediate responses to microbial pathogens and through their phagocytic
function. Examples of these receptors include membrane-bound CD14 (mCD14), a component
of the receptor for lipopolysaccharide (LPS), and MHC Class II molecules or HLA-DR, which
plays a role in antigen presentation to T lymphocytes [6].
Previous studies have yielded conflicting data as to whether lung phagocytes are modified in
CF disease with respect to phagocytic capacity. Studies of BAL neutrophils and macrophages
showed similar phagocytic capacity as those of normal children [7], or these functions were
decreased in presence of CF serum [8]. Other studies showed decreased phagocytosis of P.
aeruginosa [9] or indirect evidence of decreased phagocytosis by accumulation of apoptotic
cells in sputa and that this may be related to neutrophil elastase [10]. Expression of immune
cell-surface receptors was also examined in terminal CF by measuring antigen presenting
function of macrophages derived at the time of transplant. Cells from CF subjects had decreased
antigen presenting capacity and decreased lymphocyte activation compared to non-CF [11]. A
study in cftr knock-out animals showed increased expression of the co-stimulatory molecule
B7 (CD80) in these animals and evidence of increased expression of these surface markers in
BALF cells of CF patients [12]. It is possible that phagocytosis and antigen presentation are
compromised secondary to the chronic infection. Even at an early stage, CF airways are rich
in neutrophils and the neutrophil-derived proteases such as neutrophil elastase (NE). There is
evidence that these proteases degrade immunoglobulins [13], complement and other cell-
surface receptors [14,15] and surfactant proteins [16]. Surfactant proteins A and D (SP-A and
SP-D) are pattern recognition proteins that facilitate removal of microorganisms by serving as
opsonins in macrophage phagocytosis [17]. In CF lungs, SP-A and SP-D levels are depleted
in a manner that appears to be inversely related to the degree of neutrophilic inflammation in
the airways [18,19,20].
Recent findings in our laboratory and others suggest that exposure of lung phagocytic cells to
endotoxin may alter several important phagocyte functions and increase risk for infection. We
have found that inhalation of endotoxin by volunteers results in acutely increased expression
of HLA-DR and other dendritic cell markers (CD80, CD86) by sputum macrophages, but
reduced phagocytic capacity [21,22]. Muehlstedt et al. [23] have shown decreased HLA-DR
expression in lung cells prior to acquisition of nosocomial pneumonias. Thus, the interplay
between innate host defense elements, bacterial products, and proteolytic enzymes are all
factors potentially affecting risk for infection and the phenotypic expression of disease.
In the absence of an ideal animal model [24], an improved understanding of how inflammation
and lung disease develop in CF depends on data derived using lung cells from young CF
patients. Most previous studies of innate immune cell functions in CF have been carried out
using cells from peripheral blood or from older patients with longstanding lung disease.
Currently there are few data that directly compare the functional characteristics of lung
phagocytes (macrophages, monocytes, neutrophils) recovered from pediatric CF patients with
less severe disease, to non-CF disease controls of similar age. We therefore obtained BALF
cells from children with CF and from non-CF children undergoing bronchoscopies for clinical
indications, for assays of phagocytic function and surface receptor expression in short term
culture. Our goals were (1) to determine whether functions of cellular host defense response
are altered in CF compared to other states of lung infection, and (2) to evaluate in vitro if
addition of surfactant proteins can restore these alterations. The specific phagocyte functions
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to be studied were chosen based on our previous studies of the effects of endotoxin inhalation
on sputum phagocytes [21,22,25].
2. Materials and Methods
2.1. Study subjects
A total of 24 infants and children who underwent clinically indicated bronchoscopies
participated in the study. Exclusion criteria were the use of inhaled or systemic steroids or high
dose ibuprofen in CF patients during the 6 weeks preceding the bronchoscopy. Patients in
whom mycobacteria or viruses were detected in the bronchoalveolar lavage fluid (BALF) were
excluded from the data analysis. Informed consent was obtained from all parents and assent
from patients older than 6 years of age.
2.2. Bronchoscopy
Bronchoscopies were performed according to our clinical routine as has been described
previously [22]. Bronchoalveolar lavage (BAL) was performed in the most affected region, as
determined by infiltrates on chest radiograph or by findings seen during bronchoscopy. The
clinician performing the procedure made the choice of location for BAL. Venipuncture was
performed at the time of bronchoscopy to obtain peripheral blood cells for assays similar to
those performed on BALF cells.
2.3. Total and Differential Cell Count and Cytokine Levels
Cells and cytokines were recovered from freshly recovered BALF as has been described
previously [22]. Cytospin slides were stained with modified Wright-Giemsa stain and a
differential cell count was determined by counting a total of 200 consecutive cells, including
epithelial cells but excluding red blood cells. Cytokines in cell-free BALF supernatants were
measured using commercially available ELISA kits (R&D Systems, Minneapolis MN. USA)
2.4 Microbiology
Cultures were performed in the UNC Hospitals Clinical Microbiology Laboratory, as described
in our previous report [26]. Briefly, specimens were cultured for gram-positive and gram-
negative bacteria, and cultures and stains for viruses (including cytomegalovirus, respiratory
syncytial virus, influenza A and B, Para influenza 1–3, and adenovirus), fungi and
mycobacteria were carried out for all patients. For bacterial pathogens, a cut off value of 50,000
colony-forming units (cfu)/ml was chosen for classification of “infected” versus “non-
infected” specimens, consistent with our previous reports.
2.5 Flow Cytometry, Immunofluorescence Staining and Phagocytosis
Flow cytometric methodologies for BALF and blood cells for cell-surface marker staining
[27] and phagocytosis [28] have been described in previous reports. Briefly, flow cytometry
was performed with a FACSORT (Becton Dickinson) using an Argon-ion laser (wavelength
= 488 nm). Gain and amplitude settings were set to accommodate both blood and BAL samples.
Gates for blood cells, as well as previously established gates for BALF cells [27], were used
as general reference gates to establish the best possible gates for blood and BALF leukocyte
identification. Gating of viable macrophages, monocytes, neutrophils, and lymphocytes in
blood and BALF was based on light scatter (FSC/forward scatter, SSC/side scatter) properties
and positive expression (% positive cells) for CD45 (pan leukocyte marker) to distinguish
leukocyte populations from non-leukocyte cells and cell debris. Antibodies known to be highly
expressed (MFI) on specific cell types such as CD16 (neutrophils), HLA-DR (macrophages),
mCD14 (monocytes) and CD3 (lymphocytes) were used to gate and distinguish those cell
populations of interest. FACS analysis showed very little overlap between the cell populations
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of interest, but some overlap could not be ruled out: 98% of neutrophils were CD16 bright
positive, 95% were both CD14 and HLA-DR negative; 80% of monocytes were CD14 positive,
100% were CD3 negative and 10% were CD16 dim positive; 85% of macrophages were HLA-
DR bright positive and 6% were CD16 positive; and 100% of lymphocytes were CD3 positive
and 100% were CD14 negative.
For immunofluorescence staining, fluorescein (FITC) and phycoerythrin (PE) conjugated non-
specific antibodies of the same isotope as the receptor antibodies were used as controls to
establish background fluorescence and non-specific antibody binding. The (arithmetic) mean
fluorescence intensity (MFI) of the cells stained with control antibody was subtracted from the
MFI of the cells stained with receptor antibodies to provide a measure of receptor-specific
MFI. Relative cell size and density/granularity were quantified by analyzing light scatter
properties, namely FSC for cell size, and SSC for cell density/granularity, and recording the
mean fluorescent intensities for each. Immunofluorescence staining was performed for
mCD14, CD11b/CR3, CD64/FcγRI, CD16/FcγRIII, MHC Class II/HLA-DR, CD45, and CD3.
For phagocytosis, Saccharomyces cerevisiae zymosan A BioParticles (Molecular Probes, Inc;
Eugene, OR) conjugated to FITC were opsonized with IgG opsonizing reagent (purified rabbit
polyclonal IgG containing RIA-grade bovine serum albumin to block non-specific binding)
specific for zymosan particles. Incubation was for 45 minutes at 37°C and then the zymosan
particles were washed with RPMI 1640 two times before adjusting the particle concentration
to 2 x 106/mL. Blood cells were isolated using Lymphoprep solution (Axis-Shield PoC AS,
Oslo, Norway) and Percoll gel density centrifugation (Pharmacia, Uppsala, Sweden). Gradients
and cell isolation was performed for monocytes and neutrophils. BAL cells and purified blood
cells (2 x 106/mL) were exposed to the yeast cell walls at a ratio of 1:10 for one hour at 37°C
in the presence of human serum (20 μL) before tubes were placed on ice. Next 200 μL of 2%
paraformaldehyde was added to each tube and the tubes were stored at 4°C in the dark and
analyzed by flow cytometry (FACSORT) within 24 hours of particle exposure. Particle uptake
was identified and displayed on histogram plots as a rightward shift in FITC stained cells (FL1,
x-axis) in the phagocyte populations. Phagocytosis was determined by assessing the cells in
the zymosan-exposed population showing increased mean fluorescence intensity (MFI)
compared to cells that had not been exposed (control population, ave. MFI < 5) to zymosan
particles. The percent positive cells were the proportion of cells that right-shifted out of the
control region into the zymosan treated region as displayed on histogram plot analysis.
2.6. In Vitro Measurements
Freshly isolated BALF cells (0.5 x 106 cells/ml) from CF subjects were incubated overnight
(37°C) in 500 μl RPMI with 10% FBS, Pen/Strep, and Gentamicin (GIBCO, Invitrogen Life
Technologies, Carlsbad, CA), Amphotericin B, (Sigma, St. Louis, Mo) with or without 100
ng/ml E. coli LPS (Sigma, St. Louis, Mo.). Cells were recovered the next day, counted under
a hemacytometer and viability recorded using Trypan Blue staining. Cells were then prepared
for flow cytometric assays to measure phagocytosis and cell-surface phenotypes as described
above.
Where indicated, CF BALF cells were incubated overnight in the presence of 20 ug/ml of either
SP-A or SP-D, washed, and then subjected to surface marker and phagocytosis measurements.
These surfactant proteins preparations were kind gifts from the laboratory of Dr. Jeffrey
Whitsett, Cincinnati Childrens Hospital, Cincinnati, OH. SP-A was derived from patients with
alveolar proteinosis. SP-D was purified from BAL of SP-A −/− mice who overexpress SP-D
and this SP-D is structurally very similar to human SP-D. Purification was done by fractionation
and maltosyl-agarose column as previously described [29,30,31,32]. Endotoxin concentration
was <1 ng/ml for SP-D and < 0.06 U/ml for SP-A conditions. In other experiments, non-CF
BALF cells were incubated overnight with cell-free CF BALF supernatant (250 μl final
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concentration pooled from approximately equal volumes of BALF from 4 of the studied CF
patients), protease inhibitor (Aprotinin, 1 μM, and protease inhibitor cocktail tablets, 1 tablet
dissolved in 1.5ml H2O, Roche Applied Sciences, Indianapolis, IN) or neutrophil elastase (5.7
μg/ml final concentration, Elastin Products Co., Owensville, MO). Cells from these
experiments were washed then subjected to surface marker and phagocytosis measurements.
2.7. Data Analysis
For a given response measure, differences between CF patients and non-CF controls, and
differences between treatment and baseline, were compared using unpaired and paired non-
parametric tests (Mann-Whitney U) with the overall alpha level set at 0.05. Data are presented
as mean ± SEM unless otherwise noted. All analyses were performed using GraphPad Prism
3.0.
3. Results
3.1. Subject and Clinical Data
Indications for bronchoscopy in the CF patients were worsening respiratory symptoms
suggestive of lower airway infection. The 12 children with CF (8 males, 4 females) had a mean
age of 5.9 ± 1.2 yrs. Eight were heterozygote and 4 homozygote for the ΔF508 mutation. Eleven
of the CF patients had > 50,000 cfu/ml of one or more bacterial pathogens in BAL (S.
aureus, M. catharrhalis, H. influenzae, E. coli, P. aeruginosa). The 12 non-CF controls
consisted of 9 males and 3 females with a mean age of 4.8 ± 1.3 yrs. Indications for
bronchoscopy in non-CF patients (N=12) included recurrent pneumonia or bronchitis, upper
airway obstruction, hemoptysis, chronic cough and tracheostomy evaluation. Five non-CF
subjects had BALF infection according to our definitions, with one or more organisms (M.
catarrhalis, S. pneumoniae and H. influenzae).
3.2. Differential Cell Counts and Cytokines
BALF yield was not different between CF and non-CF children. Total and differential cell
counts showed significantly greater total number of cells and proportion of neutrophils
compared in CF to non-CF disease controls (Table 1), consistent with previous reports. Total
protein and cytokine concentrations of IL-6 and IL-8 were significantly higher, and GM-CSF
significantly reduced, in CF compared to non-CF samples. No differences in levels of IL-4,
IL-10 and IFN-γ were observed between CF patients and non-CF controls (Table 2).
3.3. Cell Surface Receptors
The cell surface markers HLA-DR and mCD14 were significantly decreased on CF vs. non-
CF BALF macrophages and monocytes (Figure 1). Other cell-surface marker molecules
(CD11b, CD64, CD16) were not different on BALF macrophages or monocytes between CF
and non-CF subjects (Table 3). In non-CF subjects, the presence of infection significantly
enhanced mCD14 expression on monocytes (124 ± 20 vs. 70 ± 11, p< 0.05) but not
macrophages (data not shown). We stratified CF patients according to the presence/absence of
P. aeruginosa. Macrophages and monocytes showed similar levels of mCD14 expression with
or without P. aeruginosa infection. Comparison of all surface markers on blood monocytes
and neutrophils showed no difference between CF and non-CF subjects (Table 3).
3.4. Comparison of phagocytosis in CF vs. non-CF neutrophils
Adequate BALF samples for phagocytosis measurements were obtained from 11 CF and 6
non-CF patients. Macrophages and neutrophils recovered from CF BALF showed blunted
phagocytosis compared to phagocytes recovered from non-CF BALF as measured by mean
fluorescence intensity (MFI) (Figure 2A). Phagocytosis, as measured by the percentage of cells
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(macrophages, neutrophils) that took up fluorescently labeled zymosan particles, was also
significantly decreased in CF versus non-CF subjects (Figure 2B). For CF subjects (dark bar),
the mean (± SEM) % of macrophages and neutrophils that took up zymosan particles was 78%
(5%) and 52% (6%), respectively. By comparison, the mean (± SEM) % of cells that took up
zymosan particles for non-CF subjects (open bar) was 91% (2%) for macrophages and 76%,
(6%) for neutrophils. Particle uptake was also demonstrated as a right-ward shift on histogram
analysis (Figures 2C and 2D). A representative histogram from a non-CF (2C) and CF subject
(2D) subject shows that CF subjects had a smaller proportion of cells that took up particles and
a greater proportion of cells that remained in the control region (M1), where no particle uptake
occurred. Unlike BALF cells, phagocytic activity (MFI) on blood monocytes and neutrophils
did not differ between CF and non-CF subjects, respectively (Mono: 273 ± 176 vs. 345 ± 73;
neutrophils: 1194 ± 322 vs. 1355 ± 181).
3.5 Effects of SP-A and SP-D on CF BALF Cells
BALF phagocytes from CF subjects (N=12) were incubated in short term culture with and
without SP-A and SP-D, and phagocytosis and surface marker expression were measured. Both
SP-A and SP-D significantly enhanced macrophage phagocytosis compared to control, with
SP-A showing a more robust response (25% increase) than SP-D (13% increase) (Figure 3A).
Incubation with LPS served as a negative control and produced an expected decrease (10%)
in phagocytosis.
With respect to surface marker expression, incubation with SP-A, but not SP-D, produced a
significant increase in mCD14 expression (p<0.05) on CF BALF phagocytes (Figure 3B). For
HLA-DR, expression tended to be enhanced by both SP-A and SP-D on macrophages and
monocytes, but these changes were not statistically significant (data not shown).
3.6.Effects of CF BALF, NE and PI on non-CF BALF Cells
Figure 4 shows the effects of cell-free CF BALF supernatant, NE and PI on non-CF cell
phagocytosis (A), mCD14 (B) and HLA-DR (C) expression. Macrophages, monocyte and
neutrophil phagocytosis from non-CF subjects was significantly blunted following incubation
with cell-free CF BALF supernatant (N=5, p<0.05) (4A). Incubation with NE significantly
decreased neutrophil phagocytosis on these subjects by 47% (N=4, p<0.05, data not shown),
and trends for reduced phagocytosis by NE were observed for macrophages and monocytes,
but these were not statistically significant. In addition, PI significantly attenuated (77%) the
decrement in monocyte phagocytosis induced by cell-free CF BALF supernatant (N=4, p<0.05,
data not shown).
CF BALF and NE significantly modified cell surface marker expression on macrophages and
monocytes from non-CF subjects. Figure 4 shows that expression of mCD14 and HLA-DR
was decreased following incubation with cell-free BALF supernatant (N=5) or with NE (N=4)
(p<0.05) (Figure 4B, 4C). The NE-induced decrements in mCD14 (4B) and HLA-DR (4C)
were significantly attenuated by PI by 75% and >100%, respectively. However, addition of PI
did not significantly attenuate decrements in mCD14 and HLA-DR expression induced by cell-
free CF BALF supernatant. This was in contrast to the attenuation of the BALF induced
decrement seen in monocyte phagocytosis.
4. Discussion
We examined whether host defense responses of lung phagocytic cells recovered by BALF
were altered in young CF subjects compared to BALF phagocytes from non-CF disease
controls. We observed that mCD14 (LPS receptor) and HLA-DR (MHC Class II) expression
were significantly reduced on CF macrophages and monocytes and that phagocytosis was
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significantly blunted. In the lung, the ability to effectively mount a host defense response
against gram-negative (LPS)/positive organisms involves recognition mechanisms, as well as
communication with adjacent trans-membrane cell surface receptors like TLR4 and TLR2, to
initiate downstream signal transduction. Decreased expression of mCD14 may lead to a weak
initiation of a series of signal transduction steps that ordinarily would induce the necessary
production of immune-enhancing factors like GM-CSF, which promotes clearance of LPS-
bearing pathogens by suppressing surfactant protein degradation [33]. In CF lungs, these
immune enhancing factors may be under-produced as we found in our CF cohort, where GM-
CSF levels were reduced compared to non-CF BALF. In the case of HLA-DR, our observation
of reduced HLA-DR expression on CF BALF macrophages supports an earlier report by Knight
and colleagues [11] who obtained BALF macrophages from terminal CF patients and found
they were unable to present antigen when compared to disease controls. Although neutrophil
elastase is not known to cleave or degrade HLA-DR, it does bind directly to a macrophage
receptor where it is internalized and has a relatively long and potentially toxic intracellular life.
This intracellular milieu may affect the internal mobilization of HLA-DR antigens and down-
regulate its expression on the cell surface. Additionally, endotoxin tolerance resulting from the
persistent presence of endotoxin in the airways, may have played a role in our decreased HLA-
DR surface expression. Evidence suggests that LPS tolerance can reduce mRNA expression
of HLA-DM and the chaparonic invariant chain [34]. It is also possible, that the presence of
some HLA-DR dim neutrophils in the macrophage gated population, may have contributed to
the overall reduced HLA-DR expression we observed on CF macrophages.
Previous studies have indirectly suggested that phagocytosis is impaired in the CF lung by
demonstrating that CF airways have increased numbers of apoptotic cells indicating defective
clearance mechanisms, [10] or by showing the effects of proteases on nonspecific phagocytosis
from non-CF or from peripheral blood [35,36]. In the current study we showed by direct means
(uptake of IgG-opsonized zymosan particles), that phagocytosis is significantly reduced on
lung phagocytes in pediatric CF lung disease. These changes were not found when peripheral
blood phagocytes were assayed suggesting that factors local to the lung microenvironment,
rather than genetic factors alone, may be responsible for the effects observed. This notion was
supported by our observation that the findings were mimicked after incubation with neutrophil
elastase in vitro.
Early evidence that soluble factors in the airway milieu of CF lungs may be contributing to
reduced phagocytosis was reported by Thomassen and colleagues [8] who found reduced
phagocytosis of CF macrophages in the presence of CF serum, suggesting that soluble factors
may be inhibiting macrophage function. We found that BALF from young CF subjects with
clinically active disease and NE were capable of reducing phagocytosis by non-CF BALF cells,
and that the attenuation induced by NE (but not CF BALF) was reversed by protease inhibitors.
This is consistent with a previous report where a 10% solution of CF lung fluid and NE inhibited
phagocytosis of apoptotic Jurkat cells by a human monocyte-derived macrophage (HMDM)
cell line [35]. In that study, an elastase inhibitor reversed phagocytosis inhibition. The lack of
complete restoration of phagocytosis by addition of protease inhibitors to CF BALF could be
secondary to other BALF factors causing defective phagocytosis. Alternatively, technical
factors such as the choice of PI, and use of human cells vs. cell lines could explain the
differences.
Further studies will be needed to define the specific mechanism of reduced phagocytosis we
observed in CF lung cells, and the causal relationships among reduced CD14, HLA-DR, and
phagocytosis, if any, remain unclear. The observation that protease inhibitor attenuated effects
of BALF supernatants on phagocytosis but not on mCD14 or HLA-DR expression may suggest
that the decrease in phagocytosis seen here are not directly linked to these surface markers.
Other mechanisms causing defective phagocytosis may include cleavage of cell-surface
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receptors that mediate phagocytosis, such as complement receptor (CD11b/CR3) or FcγRI
(CD64) for IgG-mediated phagocytosis, by proteases. Although we did not observe any
difference in CD11b or CD64 expression between CF and non-CF subjects before or after
incubation with CF BALF or NE, other phagocytosis receptors such as the phosphatidylserine
receptor, are vulnerable to cleavage by CF airway fluid (in a NE-dependent manner), and may
have contributed to the phagocytic response seen here [10]. Alternatively, cell activation
processes involved in the ingestion of bound particles may have been affected by the presence
of proteases producing attenuated function.
Here we also showed that incubation of CF phagocytes with physiologic concentrations of SP-
A or SP-D significantly enhanced phagocytosis, with SP-A having a more robust effect than
SP-D. The greater response to SP-A may be explained by the fact that SP-A enhances
phagocytosis through multiple mechanisms: as a pattern recognition molecule that binds and
opsonizes microorganisms, by directly acting on macrophages to enhance phagocytic capacity,
and by modulation of cytokine production [37]. Both SP-A and SP-D are found in abundance
in healthy lungs and play a significant role in pulmonary clearance of infectious
microorganisms, maintenance of homeostasis and resolution of inflammation. In CF lungs
however, both SP-A and SP-D [18,19] are depleted in the presence of bacterial infection, and
in inverse proportion to the degree of neutrophilic inflammation. With respect to the latter, it
appears that proteases released by activated neutrophils directly modify the levels of lung
collectins [16]. Other proteases in CF lungs besides NE are capable of degrading SP-A/SP-D
and likely contribute to reduced phagocytosis. These include cathepsin G, proteinase-3, and
metalloproteases produced by P. aeruginosa [38]. Regardless of the source of degradation,
deficient levels of surfactant proteins as seen in SP-A/D knockout mice [39], lead to reduced
phagocytic capacity of lung phagocytes. Thus our observation of partial restoration of
phagocytosis and mCD14 by surfactant protein A, shows that some of the defects are reversible
in cells from young CF patients.
Another fact to consider regarding the effect of SPA/D on CD14 expression is that SP-A/D
differentially affect the LPS-CD14 interaction depending on the type of LPS present (smooth
vs. rough). For example, both SP-A and SP-D inhibit binding of smooth LPS to CD14, but SP-
A enhances and SP-D inhibits, binding of rough LPS to CD14 [40]. The LPS used in this study
(E. coli) resembles rough LPS, hence the partial restoration we observed with SP-A on CD14
and phagocytosis, the latter increases with up-regulated CD14 expression, is consistent with
SP-A’s ability to enhance the LPS-CD14 interaction.
There were potential limitations associated with our study design. Our study was limited to
symptomatic children undergoing clinically indicated bronchoscopies. Thus, we are unable to
determine whether the changes we observed are specific for clinical exacerbation of CF lung
disease, or are a more general part of CF pathophysiology. A related potential limitation of this
study was lack of BALF from healthy age-matched controls, for ethical reasons. It is unclear
to what degree data from a heterogeneous mixture of non-CF disease controls reflect data from
true normals. In this regard, it is interesting to note that data from our non-CF children were
similar to those obtained in a previous study from our laboratory of healthy young adults using
similar protocols for measuring phagocytosis and cell-surface marker expression (HLA-DR,
mCD14) on BALF cells [27].
In summary, in young children with CF lung disease, there is evidence of decreased host
defense function of lung phagocytes that is likely due, in part, to the presence of neutrophil
elastase in the airway milieu. Furthermore, in vitro, SP-A enhances phagocytosis and
expression of immune cell-surface phenotypes (mCD14, HLA-DR) on CF phagocytes. These
findings lend support to the concept that chronic neutrophilic inflammation can have multiple
direct or indirect effects on the functions of other cells and pathways central to host defense in
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the lung. In CF, treatment strategies aimed at restoring protease/antiprotease balance and
activity of lung collectins are rational adjuncts to strategies aimed at improving the primary
defects in ion/fluid balance at the airway surface.
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mCD14 (A) and HLA-DR (B) expression (MFI) on CF (N=12, solid bar) and non-CF (N=12,
open bar) BALF macrophages and monocytes. mCD14 and HLA-DR expression were
significantly (*p<0.05) decreased in CF versus non-CF subjects.
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Phagocytosis of zymosan particles by macrophages and neutrophils recovered from BALF of
CF (N=11, solid bar) and non-CF (N=6, open bar) subjects as measured by both mean
fluorescence intensity (MFI) (2A) and % cells (macrophages, neutrophils) that took up
zymosan particles (2B). Phagocytosis on macrophages and neutrophils is significantly (*
p<0.05) decreased in the CF (solid bar) vs. non-CF (open bar) subject groups. Figures 2C and
2D show representative histograms of a non-CF and CF subject, respectively. Macrophage
phagocytosis after zymosan exposure is shown as the dark histogram. No zymosan exposure
is shown as the grey histogram. The M2 region indicates zymosan uptake by macrophages and
M1 (control region) indicates no zymosan uptake.
Alexis et al. Page 13














BALF cell culture experiments measuring phagocytosis (3A) and mCD14 expression (3B) on
macrophages obtained from 12 CF subjects 24h after incubation with SP-A, SP-D, or LPS.
Phagocytosis (MFI, % change from control) was significantly increased following SP-A and
SP-D incubation (*p<0.05). mCD14 expression (MFI, % change from control) was
significantly increased following incubation with SP-A (*p<0.05).
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BALF cell culture experiments measuring phagocytosis (4A), mCD14 (4B) and HLA-DR (4C)
expression on non-CF BALF cells after in vitro incubations with cell free CF BALF, neutrophil
elastase (NE) and these conditions with addition of proteinase inhibitor (PI). 4A: Phagocytosis
was measured in macrophages (solid bar), monocytes (open bar) and neutrophils (horizontal
hatch). Phagocytosis (MFI, % change from control) was significantly (*p<0.05) reduced for
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macrophages, monocytes and neutrophils following incubation with CF BALF (N=5); other
conditions NS and not shown. 4B and 4C show surface marker expression after BALF + PI
(N=5), NE (N=4) and NE + PI (N=4). Both, mCD14 (4B) and HLA-DR (4C) expression (MFI,
as % change from control) were significantly decreased following incubation with CF BALF
and NE (*p<0.05). PI significantly (#p<0.05) attenuated the NE-induced decrement in mCD14
and HLA-DR expression, but not the CF BALF-induced decrement.
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Table 1
























1007 (368) 22 (7) 29 (7) 12 (4) 4 (1) 29 (6) 61 (3) 66 (8)
*
significantly different than non-CF controls (p<0.05); TCC = Total Cell Count; PMN = polymorphonuclear neutrophil; Mac = Macrophage; Mono =
Monocyte; Lym = Lymphocyte; Epi = Epithelial cell
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Table 3
Cell Surface Marker Expression (MFI) on BALF and Blood Cells from CF and Non-CF Subjects (mean ± SEM)
CF Subjects CD11b/CR3 mCD14 CD64/FcγRI CD16/FcγRIII HLA-DR
BALF Mac 48 (8) 28 (5)* 26 (6) 148 (23) 106 (37)*
BALF Mono 22 (3) 28 (4)* 11 (5) 40 (9) 15 (3)*
BALF PMN 27 (2) 12 (1) 6 (2) 95 (18) 9 (4)
Blood Mono 10 (1) 96 (12) 5 (1) 25 (4) 8 (2)
Blood PMN 8 (1) 7 (1) 0 518 (59) 0
Non CF Controls
BALF Mac 41 (23) 53 (6) 35 (4) 119 (13) 416 (118)
BALF Mono 22 (10) 80 (14) 12 (2) 28 (6) 105 (26)
BALF PMN 35 (15) 11 (2) 9 (2) 110 (27) 30 (26)
Blood Mono 13 (1) 109 (19) 5 (1) 26 (7) 9 (1)
Blood PMN 9 (1) 7 (1) 0 544 (55) 0
*
significantly different from non-CF, p < 0.05; MFI = mean fluorescent intensity. Mac = Macrophage; Mono = Monocyte; PMN = Polymorphonuclear
Neutrophil
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